ISSN 1725-2423

Official Journal of the European Union

C 166

Volume 47

English edition

25 June 2004

Information and Notices

Notice No | Contents | Page

EN

(1) Text with EEA relevance

I

(Information)

COMMISSION

Euro exchange rates [1]

24 June 2004

(2004/C 166/01)

1 euro =

	Currency	Exchange rate		Currency	Exchange rate
USD	US dollar	1,2122	LVL	Latvian lats	0,6547
JPY	Japanese yen	130,32	MTL	Maltese lira	0,4259
DKK	Danish krone	7,4324	PLN	Polish zloty	4,5582
GBP	Pound sterling	0,66810	ROL	Romanian leu	40 852
SEK	Swedish krona	9,1688	SIT	Slovenian tolar	239,6400
CHF	Swiss franc	1,5130	SKK	Slovak koruna	39,938
ISK	Iceland króna	88,02	TRL	Turkish lira	1 802 919
NOK	Norwegian krone	8,3580	AUD	Australian dollar	1,7412
BGN	Bulgarian lev	1,9559	CAD	Canadian dollar	1,6330
CYP	Cyprus pound	0,58150	HKD	Hong Kong dollar	9,4526
CZK	Czech koruna	31,613	NZD	New Zealand dollar	1,9228
EEK	Estonian kroon	15,6466	SGD	Singapore dollar	2,0746
HUF	Hungarian forint	253,25	KRW	South Korean won	1 400,88
LTL	Lithuanian litas	3,4528	ZAR	South African rand	7,6491

[1] *Source:* reference exchange rate published by the ECB.

Summary of Community decisions on marketing authorizations in respect of medicinal products from 15/05/2004 to 15/06/2004

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

(2004/C 166/02)

Issuing of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93) Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
01.06.2004	Levemir	Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd,	EU/01/04/278/001-009	04.06.2004
04.06.2004	Abilifly	Otsuka Pharmaceutical Europe Ltd, Common-wealth House, 2 Chalkhill Road, Hammersmith, London W6 8DW, United Kingdom	EU/1/04/276/001-020	08.06.2004
08.06.2004	TachoSil	Nycomed Austria GMBH, St.-Peter-Strasse 25, A-4020 Linz,	EU/1/04/277/001-004	11.06.2004
15.06.2004	Oxybutynin	Nicobrand Limited, 189 Casteroe Road, Coleraine, Northerne Ireland	EU/1/03/270/001-002	18.06.2004

Modification of a marketing authorization (Article 12 of Council Regulation (EEC) No 2309/93) Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
19.05.2004	Protopic	Fujisawa GmbH, Neumarkter Str. 61, D-81673 München,	EU/1/02/201/001-006	25.05.2004
25.05.2004	Hepsera	Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom	EU/1/03/251/001	27.05.2004
26.05.2004	Viagra	Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom	EU/1/98/077/001-012	01.06.2004
26.05.2004	Combivir	Glaxo Group Ltd., Greenford Road, Greenford, Middlesex UB6 0NN United Kingdom	EU/1/98/058/001-002	01.06.2004
26.05.2004	Ziagen	Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom	EU/1/99/112/001-002	01.06.2004

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
26.05.2004	Taxotere	Aventis Pharma S.A., 20 avenue Raymond Aron, 92165 Antony Cedex, France	EU/1/95/002/001-002	01.06.2004
26.05.2004	TRIZIVIR	Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom	EU/1/00/156/001-003	01.06.2004
01.06.2004	Vivanza	Bayer AG, D-51368 Leverkusen,	EU/1/03/249/001-012	07.06.2004
01.06.2004	Levitra	Bayer AG, D-51368 Leverkusen,	EU/1/03/248/001-012	07.06.2004
01.06.2004	Epivir	Glaxo Group Ltd., Greenford Road, Greenford, Middlesex UB6 0NN, United Kingdom	EU/1/96/015/001-005	07.06.2004
08.06.2004	Remicade	Centocor B.V., Einsteinweg 101, 2333 CB Leiden, Nederland	EU/1/99/116/001-003	10.06.2004
08.06.2004	Remicade	Centocor B.V., Einsteinweg 101, 2333 CB Leiden, Nederland	EU/1/99/116/001-003	10.06.2004
08.06.2004	Fuzeon	Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom	EU/1/03/252/001-003	10.06.2004
08.06.2004	Arava	Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main,	EU/1/99/118/001-010/	18.06.2004
08.06.2004	Vfend	Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom	EU/1/02/212/001-026	10.06.2004
09.06.2004	Vfend	Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom	EU/1/02/212/001-026	11.06.2004
10.06.2004	Arava	Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main,	EU/1/99/118/001-010/	16.06.2004
10.06.2004	Viread	Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom	EU/1/01/200/001	14.06.2004

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
10.06.2004	Viread	Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom	EU/1/01/200/001	15.06.2004
10.06.2004	Herceptin	Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom	EU/1/00/145/001	14.06.2004
10.06.2004	Humira	Abbott Laboratories Ltd., Queenborough, Kent ME11 5EL, United Kingdom	EU/1/03/256/001-006	14.06.2004
10.06.2004	Trudexa	Abbott Laboratories Ltd., Queenborough, Kent ME11 5EL, United Kingdom	EU/1/03/257/001-006	14.06.2004
15.06.2004	Xigris	Eli Lilly Nederland B.V., Grootslag 1-5, 3991 RA Houten, Nederland	EU/1/02/225/001-002	17.06.2004

Prior notification of a concentration

(Case No COMP/M.3505 — TCL / ALCATEL)

[Candidate case for simplified procedure]

(2004/C 166/03)

(Text with EEA relevance)

1. On 17/06/2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1] by which TCL Communication Technology Holding Ltd ('TCL' China), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Alcatel Mobile Phone Division ('AMPD', France) by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— TCL: manufacture and distribution of mobile handsets

— AMPD: design and distribution of mobile handsets

3. On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EEC) No 4064/89 [2] it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax no. +32/2/2964301 or 2967244) or by post, under reference number COMP/M.3505 - TCL / ALCATEL, to the following address:

European Commission
Directorate-General for Competition,
Merger Registry
J-70
B-1049 Bruxelles/Brussel

---

[1] OJ L 24, 29.1.2004 p. 1.
[2] OJ C 217, 29.7.2000, p. 32; Council Regulation (EEC) No 4064/89 has been replaced by Council Regulation (EC) No 139/2004.

Non-opposition to a notified concentration

(Case No COMP/M.3391 — XCHANGING/DEUTSCHE BANK/ETB JV)

(2004/C 166/04)

(Text with EEA relevance)

On 28/04/2004, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EEC) No 4064/89. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— from the Europa competition web site (http://europa.eu.int/comm/competition/mergers/cases/) free of charge. This web site provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes.

— in electronic form in the 'CEN' version of the CELEX database, under document number 304M3391. CELEX is the computerized documentation system of European Community law. For more information on how to access Celex, see 'subscriber information' links below:

CELEX: subscriber information

http://publications.eu.int/general/en/eulaw_en.htm